JPMorgan analyst Cory Kasimov started GW Pharmaceuticals with an Overweight rating and $134 price target. The company is a "clear leader" in the field of cannabinoid science and drug development with two regulatory approvals, a "respectable" pipeline of additional assets across an array of therapeutic indications, and a proprietary research/manufacturing platform that should enable it to sustain further growth, Kasimov tells investors in a research note titled "To Be Blunt, We Think GW Could Go Higher." He believes GW's flagship product, Epidiolex is "poised for a solid launch in approved indications."